The treatment discontinuation rate was 12% for patients who received placebo, 24% for patients who received the low dose of rezpegaldesleukin, 19% for patients who received the mid dose of rezpegaldesleukin and 40% for patients who received the high dose of rezpegaldesleukin. Also, patients who received the high dose of rezpegaldesleukin had higher discontinuation rates due to adverse events than patients who received the other doses of rezpegaldesleukin.
Further studies in patients with SLE will determine the dosing and viability of this agent.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
References
- News release: Nektar Therapeutics announces phase 2 topline data for rezpegaldesleukin in patients with systemic lupus erythematosus. Nektar Therapeutics. 2023 Feb 23.
- A study of LY3471851 in adults with systemic lupus erythematosus (SLE) (ISLAND-SLE) [NCT04433585]. ClinicalTrials.gov. 2022 Aug 10.
